What are Transthyretin stabilizer drugs?

Transthyretin stabilizer drugs are pharmacologic agents that share a common mechanism (typically targeting Transthyretin (TTR)). 2 are currently marketed, with 3 more in clinical development.

What are the marketed Transthyretin stabilizer drugs?

Marketed Transthyretin stabilizer drugs include Tafamidis Meglumine Soft Capsules, Vyndaqel.

Transthyretin stabilizer

2 marketed 3 in Phase 3

This page covers all Transthyretin stabilizer drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Transthyretin (TTR).

Targets

Transthyretin (TTR)

Marketed (2)

Tafamidis Meglumine Soft Capsules · Qilu Pharmaceutical Co., Ltd. · Rare disease / Neurology / Cardiology
Tafamidis stabilizes transthyretin (TTR) protein tetramers, preventing their dissociation and misfolding into amyloid fibrils.
Vyndaqel · Foldrx Pharms · Neuroscience
Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation.

Phase 3 pipeline (3)

Acoramidis (AG10) · Eidos Therapeutics, a BridgeBio company · Rare disease / Cardiology
Acoramidis stabilizes transthyretin (TTR) protein to prevent its misfolding and aggregation, which causes amyloid disease.
AG10 oral tablet · Eidos Therapeutics, a BridgeBio company · Cardiovascular / Rare Disease
AG10 stabilizes transthyretin (TTR) protein to prevent its misfolding and aggregation, which causes amyloid deposition in cardiac and neurological tissues.
MCI-9042 · Tanabe Pharma Corporation · Neurology
MCI-9042 is a selective inhibitor of transthyretin (TTR) amyloid fibril formation that prevents the aggregation and deposition of misfolded transthyretin protein.